Sanofi and Regeneron muster combination strategies to win big with Libtayo in competitive IO field

11 May 2020 (Last Updated May 11th, 2020 09:08)

Sanofi and Regeneron's Libtayo (cemiplimab-rwlc), an anti-programmed cell death protein 1 (anti-PD-1) agent, was approved in September 2018 as an immuno-oncology (IO) drug for cutaneous squamous cell carcinoma (CSCC), which is the second most common type of cancer across the US. The drug became the sixth anti-programmed death protein 1/anti-programmed death-ligand 1 (anti-PD-1/anti-PD-L1) agent to breakthrough into the market.

In April 2020, the partnership announced that the Phase III trial of the drug to treat newly diagnosed non-small cell lung cancer (NSCLC) patients met its primary endpoints. Read more here.